迪瑞医疗：2021年第三季度报告

艾媒报告 |2019全球及中国大健康产业运行大数据及决策分析报告

本报告研究涉及企业/品牌/案例：恒瑞医药，白云山，111集团，平安好医生，好大夫在线，优健康，春雨医生，微医，丁香医生，和美医疗，北大医疗，PHG,新氧，联合丽格，正广兴家庭医生，强森医疗，微脉，美中嘉和，零氪科技，中有精准医疗，思派网络，普瑞眼科，臻和科技，移宇科技，小鹿医馆，妈咪知道，八百方，京东医药，阿里健康大药房，1药网，一心堂，健一网，好药师，健客网，美丽神器，更美，悦美，美莱整形，伊美尔，丽都整形，芝星整形，欧华美科

大健康产业细分领域的垂直深化，推动了大健康产业格局的不断完善。受政策鼓励和资本推动的影响，2019年，大健康产业在患者服务类领域、医疗服务类领域、医药服务类领域、医疗美容类领域和医疗保健类领域等细分场景快速发展。以恒瑞医药、白云山为代表的传统医药上市公司和以平安好医生、111集团和新氧科技为代表的互联网医疗上市企业各自占据大健康产业领域的一席之地。艾媒商情舆情监测系统数据显示，受2018年和2019年上半年医疗领域负面舆情的影响，大健康产业各上市企业正从低谷平稳回升。艾媒咨询分析师认为，受社会医疗需求和国家政策的推动，大健康产业仍是未来投资的亮点。

The vertical deepening of the large health industry segment has promoted the continuous improvement of the pattern of the big health industry. Influenced by policy encouragement and capital promotion, in 2019, the big health industry developed rapidly in the sub-sectors such as patient service, medical services, medical services, medical and beauty, and health care. The traditional pharmaceutical listed companies represented by Hengrui Medicine and Baiyun Mountain and the Internet medical listed companies represented by Ping An Doctor, 111 Group and New Oxygen Technology each occupy a place in the field of large health industry. According to data from the Aibu Business Intelligence Monitoring System, the listed companies in the big health industry are recovering steadily from the bottom of the market due to the negative public sentiment in the medical field in the first half of 2018 and 2019. Ai Media Consulting analysts believe that the health industry is still the highlight of future investment, driven by social medical needs and national policies.

艾媒报告|2019-2022中国医疗器械市场大数据及标杆企业运行监测报告

本报告研究涉及企业/品牌/案例：安健科技，万东医疗，康达国际，上海联影，深圳迈瑞佳能，飞利浦，柯达，西门子，GE，安健，万东，通用电气，安科，东软丹纳赫，罗氏，利德曼，强生，科华，美康，九强，日立，迈克，东芝，中生，雅培，迪瑞，大基康明，金杏，致远，成武，长庚，康健，鑫乐，瑞琦，力因精准，积水，威高，拱东，三力，阳普医疗，BD，奥凯龙，重庆多泰，成都威力生，广州暨华，威海威高，山外山，金宝，尼普洛，百特，贝朗，费森透析，美敦力，鱼疗，理邦，尚荣医疗，英科医疗

相比于全球医疗器械市场，近三年中国医疗器械市场的结构已趋向优化但结构依然严重不平衡。早期中国医疗器械市场中，中低端产品占据了将近70%的比例，而高端产品仅占30%左右的比例，而国际医疗器械市场的结构为高端产品占55%，低端产品占45%。如新华医疗、迪安诊断、乐普医疗、鱼跃医疗等积极开拓高端市场及寻求出海发展。艾媒咨询分析师认为，受人工智能、物联网、5G等技术的影响，高端化、智能化和家庭化是中国医疗器械产业发展最为显著的三大趋势。特别是医疗大数据、高端医疗影像设备、家用医疗器械、智能便携式医疗设备等领域将会备受关注。

Compared with the global medical device market, the structure of China's medical device market has been optimized in the past three years, but the structure is still seriously unbalanced. In the early Chinese medical device market, low-end products accounted for nearly 70% of the proportion, while high-end products accounted for only about 30%, while the international medical device market accounted for 55% of high-end products and 45% of low-end products. Such as Xinhua Medical, Dean Diagnostics, Lepu Medical, Yuyue Medical, etc. actively explore the high-end market and seek to develop. iiMedia Research analysts believe that high-end, intelligent and family-oriented are the three most significant trends in the development of China's medical device industry due to the impact of artificial intelligence, Internet of Things, 5G and other technologies. In particular, medical big data, high-end medical imaging equipment, home medical equipment, smart portable medical equipment and other fields will be of great concern.

艾媒咨询 | 2025年中国医用分子筛制氧行业发展白皮书

需求增长驱动医用分子筛制氧市场扩容，技术创新将推动行业向智能化、绿色化、高端化迈进。iiMedia Research（艾媒咨询）数据显示，2024年中国医用分子筛制氧机市场规模约4.25亿元，预计2029年将进一步攀升至7.06亿元。随着人口老龄化的加剧、公众健康意识的提高，以及医疗需求的增加，中国医用分子筛制氧机市场的规模在稳步扩大。同时，国家对医疗健康产业的重视程度不断提升，加之环保和新能源等领域的发展，医用分子筛制氧机在工业、医疗和家用等多个领域的应用正不断拓展。
Demand growth drives the expansion of the medical molecular sieve oxygen production market, and technological innovation will promote the industry to become intelligent, green and high-end. iiMedia Research data show that in 2024, the market size of China's medical molecular sieve oxygen generator is about 425 million yuan, and it is expected to further climb to 706 million yuan in 2029. With the increasing aging of the population, the improvement of public health awareness and the increase of medical demand, the scale of China's medical molecular sieve oxygen generator market is steadily expanding. At the same time, the state's attention to the medical and health industry continues to improve, coupled with the development of environmental protection and new energy and other fields, medical molecular sieve oxygen generator in industrial, medical and household applications are constantly expanding.

贝瑞基因：2021年第三季度报告

艾媒咨询|2021年中国医美机构市场竞争态势及企业营销模式分析报告

本报告研究涉及企业/品牌/案例：华韩整形，瑞丽医美，美莱整形，医思健康

数据显示，2016—2020年中国医美行业市场规模五年平均增长率为12.8%，与此同时，中国医美市场用户规模增长了4倍多。在人们生活水平的提升、年轻一代对医美的接受度的提高、政府监管层对医美行业的整治给医美消费者信心的提升的综合作用下，预计中国医美市场规模在2022年将达到2232亿元。随着医美产品及仪器技术水平提升、医美知识普及等，民众对整形美容的观念正在向积极态度转变，在整个行业扩张的过程中，轻医美的受众面广、门槛低、复购率高，更有可能提升市场整体渗透率，成为我国医美行业的主要增量市场。
According to the data, from 2016 to 2020, the five-year average growth rate of the market scale of China's medical and American industry was 12.8%. At the same time, the user scale of China's medical and American market increased by more than four times. Under the combined effect of the improvement of people's living standards, the improvement of the acceptance of medical beauty by the younger generation, the regulation of the medical beauty industry by the government regulators and the improvement of medical beauty consumer confidence, it is expected that the scale of China's medical beauty market will reach 223.2 billion yuan in 2022. With the improvement of the technical level of medical beauty products and instruments and the popularization of medical beauty knowledge, people's concept of plastic beauty is changing to a positive attitude. In the process of the expansion of the whole industry, light medical beauty has a wide audience, low threshold and high repurchase rate, which is more likely to improve the overall penetration rate of the market and become the main incremental market of China's medical beauty industry.

苏州麦迪斯顿医疗科技股份有限公司2021年第三季度报告

艾媒咨询｜2022年中国医疗器械行业发展状况及标杆企业研究报告

　随着国家愈发重视医疗行业的发展，鼓励创新和加速审批等利好政策不断出台，将驱动医疗器械市场进一步发展。数据显示，自2013年以来，我国医疗器械行业市场规模不断扩大，预计2022年达12529亿元，2025年将达18414亿元。

2012-2013年中国移动医疗市场年度报告

本报告是由艾媒咨询行业分析专家领衔撰写，主要分析了该行业的市场规模、发展现状与投资前景，同时对该行业的未来发展作出科学的趋势预测和专业的行业数据分析，帮助客户评估该行业的投资价值。

艾媒咨询|2021全球及中国大健康产业运行大数据及决策分析报告

本报告研究涉及企业/品牌/案例：阿里健康，联合丽格，恒瑞医药，白云山，平安好医生，111集团，新氧，药明巨诺，盘龙药业，先导药业，好大夫在线，优健康，春雨医生，丁香医生，微医

受到人口老龄化、居民患病比例增加等因素影响，国家医疗费用支出不断增加，属于刚性需求；同时，随着人们对健康标准的不断提高以及互联网医疗技术的发展，大健康产业会在相当长的时期内持续保持增长态势。数据显示，2020年中国的大健康产业营收规模超过7万亿元，预计2021年将达8万亿元，增幅达8.1%。其中，得益于大健康产业发展以及疫情期间医药需求增长，生物制药、医疗器械两大细分领域表现良好，成为2020年中国投资热度较高的新经济行业，投资项目金额分别为919亿元和273亿元。
Affected by the aging population and the increasing proportion of residents, the national medical expenditure is increasing, which belongs to the rigid demand; At the same time, with the continuous improvement of people's health standards and the development of internet medical technology, the big health industry will continue to grow for a long time. According to the data, the revenue of China's big health industry will exceed 7 trillion yuan in 2020, and it is expected to reach 8 trillion yuan in 2021, an increase of 8.1%. Among them, thanks to the development of big health industry and the growth of pharmaceutical demand during the epidemic period, biopharmaceuticals and medical devices have performed well, becoming China's new economy industry with high investment enthusiasm in 2020, with investment projects of 91.9 billion yuan and 27.3 billion yuan respectively.